Publications by authors named "S Biggi"

Recent computational advancements in the simulation of biochemical processes allow investigating the mechanisms involved in protein regulation with realistic physics-based models, at an atomistic level of resolution. These techniques allowed us to design a drug discovery approach, named Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT), based on the rationale of negatively regulating protein levels by targeting folding intermediates. Here, PPI-FIT was tested for the first time on the cellular prion protein (PrP), a cell surface glycoprotein playing a key role in fatal and transmissible neurodegenerative pathologies known as prion diseases.

View Article and Find Full Text PDF

The degradation profile and the cytotoxicity of the degradation products of a silk fibroin (SF)-based nerve conduit (SilkBridge), with a complex three-layered wall architecture comprising both native and regenerated (electrospun) fibers, are reported. The bacterial protease type XIV from was used as a hydrolytic agent at three different enzyme/substrate ratios (1:8, 1:80, and 1:800 w/w) to account for the different susceptibility to degradation of the native and regenerated components. The incubation time was extended up to 91 days.

View Article and Find Full Text PDF

Prions are misfolded proteins involved in neurodegenerative diseases of high interest in veterinary and public health. In this work, we report the chemical space exploration around the anti-prion compound BB 0300674 in order to gain an understanding of its Structure Activity Relationships (SARs). A series of 43 novel analogues, based on four different chemical clusters, were synthetized and tested against PrP and mutant PrP toxicity assays.

View Article and Find Full Text PDF

Background: A proper restoration of hip biomechanics is fundamental to achieve satisfactory outcomes after total hip arthroplasty (THA). A global hip offset (GO) postoperatively reduction of more than 5 mm was known to impair hip functionality after THA. This study aimed to verify the restoration of the GO radiographic parameter after primary THA by the use of a cementless femoral stem available in three different offset options without length changing.

View Article and Find Full Text PDF
Article Synopsis
  • Most treatments for prion diseases have tried to attack the infective form of a protein called PrP, but they haven't worked well.
  • Researchers found that a drug called chlorpromazine can help stop prion replication by moving PrP away from where it normally sits on the cell surface, but it's not safe for long-term use.
  • They have now discovered four new compounds that can reduce PrP on the cell surface and one that can also stop prions from spreading, suggesting that getting rid of PrP from cells might be a good way to treat prion diseases.
View Article and Find Full Text PDF